Literature DB >> 29337309

Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons.

Thomas Steinkellner1, Vivien Zell1, Zachary J Farino2, Mark S Sonders3, Michael Villeneuve2, Robin J Freyberg2, Serge Przedborski4,5, Wei Lu6, Zachary Freyberg2,7, Thomas S Hnasko1.   

Abstract

Parkinson's disease is characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNc). DA neurons in the ventral tegmental area are more resistant to this degeneration than those in the SNc, though the mechanisms for selective resistance or vulnerability remain poorly understood. A key to elucidating these processes may lie within the subset of DA neurons that corelease glutamate and express the vesicular glutamate transporter VGLUT2. Here, we addressed the potential relationship between VGLUT expression and DA neuronal vulnerability by overexpressing VGLUT in DA neurons of flies and mice. In Drosophila, VGLUT overexpression led to loss of select DA neuron populations. Similarly, expression of VGLUT2 specifically in murine SNc DA neurons led to neuronal loss and Parkinsonian behaviors. Other neuronal cell types showed no such sensitivity, suggesting that DA neurons are distinctively vulnerable to VGLUT2 expression. Additionally, most DA neurons expressed VGLUT2 during development, and coexpression of VGLUT2 with DA markers increased following injury in the adult. Finally, conditional deletion of VGLUT2 made DA neurons more susceptible to Parkinsonian neurotoxins. These data suggest that the balance of VGLUT2 expression is a crucial determinant of DA neuron survival. Ultimately, manipulation of this VGLUT2-dependent process may represent an avenue for therapeutic development.

Entities:  

Keywords:  Mouse models; Neurodegeneration; Neuroscience; Parkinson’s disease

Mesh:

Substances:

Year:  2018        PMID: 29337309      PMCID: PMC5785252          DOI: 10.1172/JCI95795

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  68 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Expression of the vesicular glutamate transporters during development indicates the widespread corelease of multiple neurotransmitters.

Authors:  Jean-Luc Boulland; Tayyaba Qureshi; Rebecca P Seal; Amina Rafiki; Vidar Gundersen; Linda H Bergersen; Robert T Fremeau; Robert H Edwards; Jon Storm-Mathisen; Farrukh A Chaudhry
Journal:  J Comp Neurol       Date:  2004-12-13       Impact factor: 3.215

3.  Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function.

Authors:  Jamie Raudensky; Bryan K Yamamoto
Journal:  Brain Res       Date:  2007-01-02       Impact factor: 3.252

4.  Vesicular glutamate transport promotes dopamine storage and glutamate corelease in vivo.

Authors:  Thomas S Hnasko; Nao Chuhma; Hui Zhang; Germaine Y Goh; David Sulzer; Richard D Palmiter; Stephen Rayport; Robert H Edwards
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

5.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

6.  Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate.

Authors:  Garret D Stuber; Thomas S Hnasko; Jonathan P Britt; Robert H Edwards; Antonello Bonci
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

7.  Glutamatergic and dopaminergic neurons in the mouse ventral tegmental area.

Authors:  Tsuyoshi Yamaguchi; Jia Qi; Hui-Ling Wang; Shiliang Zhang; Marisela Morales
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

8.  Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.

Authors:  J S Schneider; A Yuwiler; C H Markham
Journal:  Brain Res       Date:  1987-05-12       Impact factor: 3.252

9.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

Review 10.  Glutamate in dopamine neurons: synaptic versus diffuse transmission.

Authors:  Laurent Descarries; Noémie Bérubé-Carrière; Mustapha Riad; Grégory Dal Bo; J Alfredo Mendez; Louis-Eric Trudeau
Journal:  Brain Res Rev       Date:  2007-10-26
View more
  35 in total

Review 1.  Dopamine-glutamate neuron projections to the nucleus accumbens medial shell and behavioral switching.

Authors:  Susana Mingote; Aliza Amsellem; Abigail Kempf; Stephen Rayport; Nao Chuhma
Journal:  Neurochem Int       Date:  2019-06-03       Impact factor: 3.921

Review 2.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

3.  Roles of dopamine and glutamate co-release in the nucleus accumbens in mediating the actions of drugs of abuse.

Authors:  Silas A Buck; Mary M Torregrossa; Ryan W Logan; Zachary Freyberg
Journal:  FEBS J       Date:  2020-08-11       Impact factor: 5.542

Review 4.  Classification of Midbrain Dopamine Neurons Using Single-Cell Gene Expression Profiling Approaches.

Authors:  Jean-Francois Poulin; Zachary Gaertner; Oscar Andrés Moreno-Ramos; Rajeshwar Awatramani
Journal:  Trends Neurosci       Date:  2020-02-11       Impact factor: 13.837

5.  Neonatal Nicotine Exposure Primes Midbrain Neurons to a Dopaminergic Phenotype and Increases Adult Drug Consumption.

Authors:  Benedetto Romoli; Adrian F Lozada; Ivette M Sandoval; Fredric P Manfredsson; Thomas S Hnasko; Darwin K Berg; Davide Dulcis
Journal:  Biol Psychiatry       Date:  2019-04-24       Impact factor: 13.382

6.  VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation.

Authors:  Willemieke M Kouwenhoven; Guillaume Fortin; Anna-Maija Penttinen; Clélia Florence; Benoît Delignat-Lavaud; Marie-Josée Bourque; Thorsten Trimbuch; Milagros Pereira Luppi; Alix Salvail-Lacoste; Pascale Legault; Jean-François Poulin; Christian Rosenmund; Raj Awatramani; Louis-Éric Trudeau
Journal:  J Neurosci       Date:  2020-09-14       Impact factor: 6.167

7.  Skeletal muscle transcriptional networks linked to type I myofiber grouping in Parkinson's disease.

Authors:  Kaleen M Lavin; Stuart C Sealfon; Merry-Lynn N McDonald; Brandon M Roberts; Katarzyna Wilk; Venugopalan D Nair; Yongchao Ge; Preeti Lakshman Kumar; Samuel T Windham; Marcas M Bamman
Journal:  J Appl Physiol (1985)       Date:  2019-12-12

8.  Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments.

Authors:  Yuan Cai; Beatriz E Nielsen; Emma E Boxer; Jason Aoto; Christopher P Ford
Journal:  Neuron       Date:  2021-02-17       Impact factor: 17.173

Review 9.  Glutamate homeostasis and dopamine signaling: Implications for psychostimulant addiction behavior.

Authors:  Kathryn D Fischer; Lori A Knackstedt; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2020-11-05       Impact factor: 3.921

Review 10.  Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson's Disease.

Authors:  Xiang Li; Wenjun Wang; Jianghong Yan; Fancai Zeng
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.